Concepedia

GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders

Lorenzo Leggio, Christian S. Hendershot, Mehdi Farokhnia, Anders Fink‐Jensen, Mette Kruse Klausen, Joseph P. Schacht, W. Kyle Simmons

Nature Medicine · 2023 · 85 citations · 11 references

DOIFull text

Open access

Concepts

References

11

Genome-wide association study of alcohol consumption and genetic overlap with other health-related traits in UK Biobank (N=112 117)

Mark J. Adams, Gail Davies, David M. Howard et al. · Molecular Psychiatry · 2017 · 498 citations · Full text

, , +12

Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial

Mette Kruse Klausen, Mathias E. Jensen, Marco Møller et al. · JCI Insight · 2022 · 219 citations · Full text

, , +15

The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission

Vicky Chuong, Mehdi Farokhnia, Sophia Khom et al. · JCI Insight · 2023 · 204 citations · Full text

, , +16

Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats

Cajsa Aranäs, Christian E. Edvardsson, Olesya T. Shevchouk et al. · EBioMedicine · 2023 · 146 citations · Full text

, , +16

The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence

Petra Suchankova, Jia Yan, Melanie L. Schwandt et al. · Translational Psychiatry · 2015 · 137 citations · Full text

, , +17